Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE and next-generation, highly selective ...

Could the first confirmed signal from an extraterrestrial source be less a hello than a goodbye? Astrophysicist David Kipping argues as much, and his “Eschatian Hypothesis” reimagines the way ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...

Practice CBSE Class 12 Physics Top 50 MCQs with Answers based on the latest syllabus and exam pattern. Prepare effectively ...

BHPian BlackBeard recently shared this with other enthusiasts:Hello folks. Since many enthusiasts here are keen on knowing ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

Addressing the core issues of latency and integration in developing audio amplifiers for today’s smart cockpits.

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...

Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of its latest peer-reviewed paper in Scientific Reports: "A brief visual ...